References
- Brewer E J. The last thirty and the next ten years. J Rheumatol 1992; 19(Suppl 33)108–9
- Brewer E J, Gianninl E H, Kuzmina N, Alekseev L. o-peni-cillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. N Engl J Med 1986; 314: 1269–76
- Glanninl E H, Brewer E J, Kuzmina N, et al. Methotrexate treatment of recalcitrant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double blind placebo-controlled trial. N Engl J Med 1992; 326: 1043–9
- Glanninl E H, Brewer E J, Kuzmina N, et al. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled cooperative trial. Arthritis Rheum 1990; 33: 466–76
- Cassidy J T, Petty R E. Textbook of Pediatric Rheumatology, 2nd edn. Churchill Livingstone, New York 1990; 6–10
- Fink C W. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995; 22: 1566–9
- Gianninl E H, Lovell D J, Felson D T, Goldsmith C H. Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis Rheum 1994; 37: S428
- Gianninl E H, Ruperto N, Ravelli A, Lovell D J, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum, in press
- Pincus T, Stein C M. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observation, or clinical protocols. J Rheumatol 1995; 22: 1611–7
- O'Dell J, Haire C, Erlckson N, et al. Triple DMARO therapy for rheumatoid arthritis is well-tolerated. Arthritis Rheum 1994; 37: S295
- Bulpitt K J, Clements P J, Lachenbruch P A, et al. Magnitude of dysfunction in early rheumatoid arthritis (<1 year symptoms). Arthritis Rheum 1994; 37: S199